Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZIPANGU: Ranibizumab +/- Laser for BRVO Macular Edema
NCT02953938Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2016
- Primary completion
- Dec 2018
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ranibizumab in macular edema (2 arms), sponsored by Novartis. Primary endpoint: Difference in Mean Number of Ranibizumab Injections. Started Dec 2016; status: completed.
02
Drugs
ranibizumab
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT02953938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02953938.